^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCL4 elevation

i
Other names: CCL4, Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4, Chemokine (C-C motif) ligand 4
Entrez ID:
Related biomarkers:
5d
Boldine protects against carbon tetrachloride-induced chronic liver injury by regulating NF-κB signaling pathway. (PubMed, J Biochem Mol Toxicol)
Boldine administration also repressed α-SMA expression. The results of this study demonstrate the antioxidant, anti-inflammatory, and antifibrotic properties of boldine, and it can be a potential therapeutic candidate in the treatment of CLD.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CCL4 (Chemokine (C-C motif) ligand 4) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL1B (Interleukin 1, beta)
|
CCL4 elevation
5ms
MFAP2 promotes HSCs activation through FBN1/TGF-β/Smad3 pathway. (PubMed, J Cell Mol Med)
In vitro results showed that the inhibition of MFAP2 alleviated hepatic fibrosis by inhibiting the activation and inducing the apoptosis of active HSCs in a CCl4-induced mouse model. In conclusion, our results suggest that MFAP2 is a potential target for the clinical treatment of liver fibrosis.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • FBN1 (Fibrillin 1) • SMAD3 (SMAD Family Member 3)
|
CCL4 elevation
8ms
Liver resection modulates hepatic chemokine levels in breast cancer. (PubMed, Surgery)
Our study showed elevation and variations in chemokines after hepatectomy, with a prominent increase in pro-tumorigenic chemokines. These results can be associated with the acceleration of metastasis after liver resection. However, further prospective studies are required to better define the impact of resection, which may transform the liver into a favorable site for metastasis.
Journal
|
CCL2 (Chemokine (C-C motif) ligand 2) • CCL3 (C-C Motif Chemokine Ligand 3)
|
CCL4 elevation
8ms
GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. (PubMed, Int J Mol Sci)
Using paired tumor biopsies, we found that tumor-infiltrating immune cells had a reduced expression of inhibitory immune checkpoints (VISTA, PD-1, PD-L2) and an elevated expression of T-cell activation markers (CTLA-4, OX40L) after elraglusib treatment. These results address a significant gap in knowledge concerning the immunomodulatory mechanisms of GSK-3 inhibitor elraglusib, provide a rationale for the clinical evaluation of elraglusib in combination with immune checkpoint blockade, and are expected to have an impact on additional tumor types, besides CRC.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker • Biopsy • Immune cell
|
KDR (Kinase insert domain receptor) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • GDF15 (Growth differentiation factor 15) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • CCL22 (C-C Motif Chemokine Ligand 22) • GSDMB (Gasdermin B) • IL1B (Interleukin 1, beta) • RELA (RELA Proto-Oncogene)
|
VEGFA elevation • CCL4 elevation • GSDMB expression
|
elraglusib (9-ING-41)
over1year
Modulation of miR-192/NF-κB/ TGF-β/ E-cadherin by thymoquinone protects against diethylnitrosamine /carbon tetrachloride hepatotoxicity. (PubMed, Physiol Int)
In conclusion, thymoquinone protected the liver tissues through preserving miR-192 and E-cadherin and aborting NF-κB & TGF-β signaling. The current results highlight a new role for thymoquinone in preventing hepatic tumorigenesis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • AFP (Alpha-fetoprotein) • BAX (BCL2-associated X protein) • TGFB1 (Transforming Growth Factor Beta 1) • MIR192 (MicroRNA 192)
|
BCL2 expression • CDH1 expression • BAX expression • CCL4 elevation • miR-192 expression
over2years
STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma. (PubMed, Acta Haematol)
Tumor xenograft models showed that si-STAT3 inhibited tumor growth in vivo and decreased proliferative and mitogenic activities in tumor tissues, findings that were consistent with the in vitro data. Hence, this study provides new evidence that STAT3 and CCL4 may be new prognostic biomarkers and therapeutic targets for treating DLBCL.
Journal
|
CCL4 (Chemokine (C-C motif) ligand 4)
|
STAT3 expression • CCL4 elevation
almost3years
CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cells. (PubMed, Neoplasma)
The revealed involvement of CD150 and CD180 in cytokine regulation expands our knowledge of the role of CD150 and CD180 in the pathobiology of CLL and their contribution to a favorable clinical outcome. Determining the cytokines expression levels together with CD150 and CD180 expression status may help to predict the responsiveness of CLL B cells to chemotherapeutic drugs and optimize personalized chemotherapy scheme.
Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • CCL4 (Chemokine (C-C motif) ligand 4)
|
CCL4 elevation
3years
Possible Protective Potency of Argun Nut (Medemia argun - An Ancient Egyptian Palm) against Hepatocellular Carcinoma in Rats. (PubMed, Nutr Cancer)
The HCC group showed decreased antioxidant defense and BAX/Bcl-2 ratio. This study assumes that MA has a chemo-preventive effect against hepatocarcinogenesis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AFP (Alpha-fetoprotein) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
CCL4 elevation
over3years
Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinoma-An Emerging Role for Chemokines. (PubMed, Cancers (Basel))
Comparison of matched pre- and post-treatment serum (n = 28) showed a large reduction in VEGFC, and a concomitant increase in other cytokines, including CCL4. These data link several serum markers with clinical outcomes, highlighting an important role for immune cell trafficking in the EAC antitumor immune response.
Clinical • Clinical data • Journal
|
IL10 (Interleukin 10) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22)
|
CCL4 elevation
over3years
Anti-OX40 antibody directly enhances the function of tumor-reactive CD8 T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. (PubMed, Clin Cancer Res)
These results highlight a critical role of OX40 activation in potentiating the effector function of tumor-reactive CD8 T cells and suggest further evaluation of OX40 agonist-based combinations in patients with immune-resistant tumors.
Journal • IO biomarker
|
BRAF (B-raf proto-oncogene) • PTEN (Phosphatase and tensin homolog) • CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL4 (Chemokine (C-C motif) ligand 4)
|
BRAF mutation • TNFRSF4 expression • CCL4 elevation • PTEN loss • TILs
|
GSK2636771
almost4years
Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients. (PubMed, Cancer Cell Int)
Among them, high levels of B cells, CD8T cells, neutrophils and dendritic cells were significantly related to longer SKCM survival time. In summary, this study mainly identified five chemokine members (CXCL9, CXCL10, CXCL13, CCL4, CCL5) associated with SKCM tumorigenesis, progression, prognosis and immune infiltrations, which might help us evaluate several immune-related targets for cutaneous melanoma therapy.
Clinical • Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL5 (Chemokine (C-C motif) ligand 5) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL10 (Interleukin 10) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CCL4 (Chemokine (C-C motif) ligand 4) • IRF1 (Interferon Regulatory Factor 1)
|
IRF1 expression • CCL4 elevation
almost4years
Polysaccharides from Enteromorpha prolifera protect against carbon tetrachloride-induced acute liver injury in mice via activation of Nrf2/HO-1 signaling, and suppression of oxidative stress, inflammation and apoptosis. (PubMed, Food Funct)
Moreover, EPP prevented the hepatocellular apoptotic changes with inhibition of B-cell lymphoma 2 (Bcl-2), and the induction of Bcl-2-associated X (Bax) and Cleaved caspase-3 caused by CCl4. Taken together, these results indicated that EPP protected against hepatic injury induced by CCl4-derived reactive intermediates through the activation of Nrf2/HO-1 signaling, and suppression of oxidative stress, inflammation and apoptosis.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • HMOX1 (Heme Oxygenase 1) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3) • CCL4 (Chemokine (C-C motif) ligand 4) • TLR4 (Toll Like Receptor 4)
|
CCL4 elevation